PDF herunterladen
Klin Monbl Augenheilkd 2010; 227(6): R79-R92
DOI: 10.1055/s-0030-1249988
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Therapiestrategien bei nicht infektiösen entzündlichen Augenerkrankungen – Wann sollte welche systemische Therapie begonnen werden?

C. Heinz1 , 2 , A. Heiligenhaus1 , 2 , M. Becker3
  • 1Augenabteilung am St. Franziskus Hospital Münster
  • 2Universitätsaugenklinik, Universität Duisburg-Essen
  • 3Stadtspital Triemli, Augenklinik
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. Juni 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Einleitung

Zur Therapie einer Uveitis oder Skleritis werden in erster Linie topische und systemische Kortikosteroide genutzt. Abhängig von Lokalisation und Schwere der Entzündung ist hiermit häufig kurzfristig Reizfreiheit zu erzielen. Gelegentlich wird damit aber keine Rückbildung der Beschwerden erlangt, sodass eine nicht steroidale immunsuppressive Therapie erforderlich wird. In dieser Übersicht sollen die Therapiestrategien bei Patienten mit nicht infektiöser Uveitis und Skleritis unter besonderer Berücksichtigung nicht steroidaler systemischer Therapie dargelegt werden. Ziel ist es, dem Augenarzt die aktuellen entzündungshemmenden Therapieoptionen, deren Kontraindikationen und wichtige unerwünschte Medikamentenwirkungen darzulegen.

Literatur

  • 1 Jabs D A, Nussenblatt R B, Rosenbaum J T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop.  Am J Ophthalmol. 2005;  140 509-516
    CrossrefPubMedGoogle Scholar
  • 2 Gritz D C, Wong I G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.  Ophthalmology. 2004;  111 491-500 discussion 500
    CrossrefPubMedGoogle Scholar
  • 3 Smith J R, Mackensen F, Rosenbaum J T. Therapy insight: scleritis and its relationship to systemic autoimmune disease.  Nat Clin Pract. 2007;  3 219-226
    CrossrefPubMedGoogle Scholar
  • 4 Haynes B F, Fishman M L, Fauci A S et al. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature.  Am J Med. 1977;  63 131-141
    CrossrefPubMedGoogle Scholar
  • 5 Dunne J A, Jacobs N, Morrison A et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin.  Br J Ophthalmol. 1985;  69 120-125
    CrossrefPubMedGoogle Scholar
  • 6 Sand B B, Krogh E. Topical indometacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled clinical trial of non-steroid versus steroid anti-inflammatory treatment.  Acta Ophthalmol (Copenh). 1991;  69 145-148
    PubMedGoogle Scholar
  • 7 Weijtens O, Feron E J, Schoemaker R C et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection.  Am J Ophthalmol. 1999;  128 192-197
    CrossrefPubMedGoogle Scholar
  • 8 Weijtens O, Schoemaker R C, Romijn F P et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate.  Ophthalmology. 2002;  109 1887-1891
    CrossrefPubMedGoogle Scholar
  • 9 Weijtens O, van der Sluijs F A, Schoemaker R C et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection.  Am J Ophthalmol. 1997;  123 358-363
    PubMedGoogle Scholar
  • 10 Benitez-Del-Castillo J M, Garcia-Sanchez J, Iradier T et al. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.  Eye (Lond). 2000;  14 (Pt 3A) 340-343
    PubMedGoogle Scholar
  • 11 Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behcet disease.  Annals of the Rheumatic Diseases. 2008;  67 1656-1662
    CrossrefPubMedGoogle Scholar
  • 12 Sfikakis P P, Markomichelakis N, Alpsoy E et al. Anti-TNF therapy in the management of Behcet's disease – review and basis for recommendations.  Rheumatology (Oxford, England). 2007;  46 736-741
    CrossrefPubMedGoogle Scholar
  • 13 Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study.  Archives of Dermatology. 2002;  138 467-471
    CrossrefPubMedGoogle Scholar
  • 14 Becker M D, Heiligenhaus A, Hudde T et al. Interferon as a treatment for uveitis associated with multiple sclerosis.  Br J Ophthalmol. 2005;  89 1254-1257
    CrossrefPubMedGoogle Scholar
  • 15 Heiligenhaus A, Duck N, Michel D et al. Indication and effect of immunosuppression in patients with scleritis.  Klin Monatsbl Augenheilkd. 2003;  220 471-480
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 16 Jabs D A, Mudun A, Dunn J P et al. Episcleritis and scleritis: clinical features and treatment results.  Am J Ophthalmol. 2000;  130 469-476
    CrossrefPubMedGoogle Scholar
  • 17 Watson P G, Young R D. Scleral structure, organisation and disease. A review.  Experimental Eye Research. 2004;  78 609-623
    CrossrefPubMedGoogle Scholar
  • 18 Bauer A M, Fiehn C, Becker M D. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis.  Am J Ophthalmol. 2005;  139 1086-1089
    CrossrefPubMedGoogle Scholar
  • 19 Sainz de la Maza M, Jabbur N S, Foster C S. An analysis of therapeutic decision for scleritis.  Ophthalmology. 1993;  100 1372-1376
    PubMedGoogle Scholar
  • 20 Sen H N, Suhler E B, Al-Khatib S Q et al. Mycophenolate mofetil for the treatment of scleritis.  Ophthalmology. 2003;  110 1750-1755
    CrossrefPubMedGoogle Scholar
  • 21 Soukiasian S H, Foster C S, Raizman M B. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.  Am J Ophthalmol. 1994;  118 601-611
    PubMedGoogle Scholar
  • 22 Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis.  Br J Ophthalmol. 1989;  73 743-746
    CrossrefPubMedGoogle Scholar
  • 23 Taylor S R, Salama A D, Joshi L et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.  Arthritis and Rheumatism. 2009;  60 1540-1547
    CrossrefPubMedGoogle Scholar
  • 24 Doctor P, Sultan A, Syed S et al. Infliximab for the treatment of refractory scleritis.  Br J Ophthalmology. 2010;  94 (5) 579-583
    CrossrefPubMedGoogle Scholar
  • 25 Meyer P A, Watson P G, Franks W et al. ‘Pulsed immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease.  Eye. 1987;  1 (Pt 4) 487-495
    CrossrefPubMedGoogle Scholar
  • 26 Wessels J A, Huizinga T W, Guchelaar H J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.  Rheumatology. 2008;  47 249-255
    CrossrefPubMedGoogle Scholar
  • 27 Samson C M, Waheed N, Baltatzis S et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients.  Ophthalmology. 2001;  108 1134-1139
    CrossrefPubMedGoogle Scholar
  • 28 van Ede A E, Laan R F, Rood M J et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2001;  44 1515-1524
    CrossrefPubMedGoogle Scholar
  • 29 Gangaputra S, Newcomb C W, Liesegang T L et al. Methotrexate for ocular inflammatory diseases.  Ophthalmology. 2009;  116 2188-2198 e2181
    CrossrefPubMedGoogle Scholar
  • 30 Hesselink D A, Baarsma G S, Kuijpers R W et al. Experience with cyclosporine in endogenous uveitis posterior.  Transplant Proc. 2004;  36 372S-377S
    CrossrefPubMedGoogle Scholar
  • 31 Zierhut M, Stubiger N, Aboalchamat W et al. Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis.  Ophthalmologe. 2001;  98 647-651
    CrossrefPubMedGoogle Scholar
  • 32 Baltatzis S, Tufail F, Yu E N et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.  Ophthalmology. 2003;  110 1061-1065
    CrossrefPubMedGoogle Scholar
  • 33 Daniel E, Thorne J E, Newcomb C W et al. Mycophenolate mofetil for ocular inflammation.  Am J Ophthalmol. 2009;  149 423-432 e421-422
    CrossrefPubMedGoogle Scholar
  • 34 Pasadhika S, Kempen J H, Newcomb C W et al. Azathioprine for ocular inflammatory diseases.  Am J Ophthalmol. 2009;  148 500-509 e502
    CrossrefPubMedGoogle Scholar
  • 35 Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period.  J Rheumatol. 2003;  30 1277-1279
    PubMedGoogle Scholar
  • 36 Pujari S S, Kempen J H, Newcomb C W et al. Cyclophosphamide for ocular inflammatory diseases.  Ophthalmology. 2009;  117 356-365
    CrossrefPubMedGoogle Scholar
  • 37 Dick A D, Forrester J V, Liversidge J et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).  Progress in Retinal and Eye Research. 2004;  23 617-637
    CrossrefPubMedGoogle Scholar
  • 38 Diel R, Hauer B, Loddenkemper R et al. Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen.  Pneumologie. 2009;  63 329-334
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Foster C S, Tufail F, Waheed N K et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.  Archives of Ophthalmology. 2003;  121 437-440
    CrossrefPubMedGoogle Scholar
  • 40 Galor A, Perez V L, Hammel J P et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.  Ophthalmology. 2006;  113 2317-2323
    CrossrefPubMedGoogle Scholar
  • 41 Sieper J, Koenig A, Baumgartner S et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.  Annals of the Rheumatic Diseases. 2010;  69 226-229
    CrossrefPubMedGoogle Scholar
  • 42 Diaz-Llopis M, Garcia-Delpech S, Salom D et al. Adalimumab therapy for refractory uveitis: a pilot study.  J Ocul Pharmacol Ther. 2008;  24 351-361
    CrossrefPubMedGoogle Scholar
  • 43 Suhler E B, Smith J R, Giles T R et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.  Archives of Ophthalmology. 2009;  127 819-822
    CrossrefPubMedGoogle Scholar
  • 44 Suhler E B, Smith J R, Wertheim M S et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.  Archives of Ophthalmology. 2005;  123 903-912
    CrossrefPubMedGoogle Scholar
  • 45 Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial.  Arthritis and Rheumatism. 2005;  52 2478-2484
    CrossrefPubMedGoogle Scholar
  • 46 Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 1692-1695
    CrossrefPubMedGoogle Scholar
  • 47 Gueudry J, Wechsler B, Terrada C et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease.  Am J Ophthalmol. 2008;  146 837-844 e831
    CrossrefPubMedGoogle Scholar
  • 48 Deuter C M, Kotter I, Gunaydin I et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis.  Br J Ophthalmol. 2009;  93 906-913
    CrossrefPubMedGoogle Scholar
  • 49 Sadreddini S, Noshad H, Molaeefard M et al. Treatment of retinal vasculitis in Behcet's disease with rituximab.  Modern Rheumatology/The Japan Rheumatism Association. 2008;  18 306-308
    PubMedGoogle Scholar
  • 50 Tappeiner C, Heinz C, Specker C et al. Rituximab as a treatment option for refractory endogenous anterior uveitis.  Ophthalmic Research. 2007;  39 184-186
    CrossrefPubMedGoogle Scholar

Dr. med. Carsten Heinz

Augenabteilung am St. Franziskus Hospital Münster

Hohenzollernring 74

48145 Münster

eMail: carsten.heinz@uveitis-zentrum.de

      >